Becton Dickinson (XSWX:BDX) 3-1 Month Momentum %: 5.92% (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BDX Becton Dickinson & Co XSWX:BDX
79 GF Score
Price CHF134.04
GF Value CHF151.55
! 4 Warning Signs
View Full Analysis

What is Becton Dickinson 3-1 Month Momentum %?

Becton Dickinson XSWX:BDX +2.70% 79 3-1 Month Momentum % is 5.92% as of Jul. 29, 2026. GuruFocus rates XSWX:BDX with a GF Score™ of 79/100 and a GF Value™ of CHF151.55. The stock has 4 warning signs investors should review. Among 843 Medical Devices & Instruments companies, Becton Dickinson ranks better than 74.5% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-29), Becton Dickinson's 3-1 Month Momentum % is 5.92%.

The industry rank for Becton Dickinson's 3-1 Month Momentum % or its related term are showing as below:

XSWX:BDX's 3-1 Month Momentum % is ranked better than
74.5% of 843 companies
in the Medical Devices & Instruments industry
Industry Median: -8.51 vs XSWX:BDX: 5.92

Becton Dickinson  (XSWX:BDX) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Becton Dickinson 3-1 Month Momentum % Related Terms


XSWX:BDX vs MDLN, RMD, WST: 3-1 Month Momentum % Comparison

For the Medical Instruments & Supplies subindustry, Becton Dickinson's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Becton Dickinson 3-1 Month Momentum % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Becton Dickinson's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Becton Dickinson's 3-1 Month Momentum % falls into.


XSWX:BDX
79GF Score
Becton Dickinson & Co XSWX:BDX
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Becton Dickinson  (XSWX:BDX) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of 5.92% mean?
Becton Dickinson (XSWX:BDX) has a 3-1 Month Momentum % of 5.92% as of Jul. 29, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Becton Dickinson and its competitors. According to the industry distribution chart, Becton Dickinson ranks #215 out of 843 companies in the Medical Devices & Instruments industry, placing it in the top 25.5%.
Is Becton Dickinson's 3-1 Month Momentum % too high?
Becton Dickinson's current 3-1 Month Momentum % is 5.92%. Based on the distribution chart, Becton Dickinson ranks #215 out of 843 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Becton Dickinson has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Becton Dickinson's 3-1 Month Momentum % compare to MDLN and RMD?
According to the Medical Devices & Instruments industry distribution chart, Becton Dickinson ranks #215 out of 843 companies for 3-1 Month Momentum %. This puts Becton Dickinson in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Becton Dickinson and its competitors. Becton Dickinson's current 3-1 Month Momentum % is 5.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Becton Dickinson stock overvalued right now?
Becton Dickinson (XSWX:BDX) has a current 3-1 Month Momentum % of 5.92%. The stock's GF Value™ is CHF151.55, compared to a current price of CHF134.04 — trading 11.6% below its estimated fair value. The current 3-1 Month Momentum % is 5.92%. Becton Dickinson's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Becton Dickinson (XSWX:BDX), the current 3-1 Month Momentum % is 5.92% as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Becton Dickinson (XSWX:BDX) Overvalued in 2026?

Based on GuruFocus' analysis, Becton Dickinson stock appears to be undervalued. The current stock price of CHF134.04 is trading 11.6% below its estimated GF Value™ of CHF151.55.

Key valuation signals for XSWX:BDX:

  • 3-1 Month Momentum %: 5.92%
  • GF Value™: CHF151.55 vs. price of CHF134.04 (11.6% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the XSWX:BDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Becton Dickinson Business Description

Address 1 Becton Drive, Franklin Lakes, NJ, USA, 07417-1880
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
79GF Score

Get the complete analysis for XSWX:BDX

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF134.04
Price
CHF151.55
GF Value